Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Friday, October 24, 2014

New paper associates colorectal cancer with trimethylamine-oxide

Paper : TMAO and colorectal cancer
A new research paper by researchers at Cornell University have hypothesized that trimethylame-n-oxide (TMAO) may be associated with colorectal cancer. This would be the 2nd major disease to be hypothesized to be associated with higher TMAO levels. The other is heart disease, first postulated in 2012 by Dr Stanley Hazen et al at Cleveland Clinic.

Paper :  
Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study : Link
Cornell University

How might this help trimethylaminuria ?  
For people who feel they have a metabolic malodor problem caused solely by trimethylamine, now that TMAO has been associated with 2 major diseases in humans, it is likely that much research will now take place regarding trimethylamine in humans, and possibly how to prevent or neutralise it. So TMAU patients are likely to be a big benefactor of this research.

TMAO and TMA
Trimethylamine-n-oxide (TMAO) is oxidized trimethylamine (TMA). Trimethylamine in humans is thought to be generated solely from any TMA or TMAO ingested (e.g. fish), or by gut flora altering TMA precursors in the diet (such as choline and carnitine). In healthy humans the TMA is oxidized by FMO3 enzyme into TMAO and then excreted. You would think that TMAU people would not have high TMAO levels (and so less likely to be exposed to a hypothesized Heart Disease or cancer risk), but in many cases it seems TMAU people have both high TMA and TMAO levels. Keep in mind the connection to these 2 major diseases is not the consensus (yet).       

FMO3
While they are likely to be looking at ways of reducing/blocking TMA, at the moment we do not know if they will take an interest in FMO3 enzyme and it's proper functioning as well. Currently FMO3 is a 'mixed function oxidase' enzyme generally regarded as a 'negligible' player in the grand scheme of enzymes in the body, although this is likely an underestimation. However, if they stop/reduce/neutralise TMA then they may not feel it necessary to look at ways to make FMO3 function properly. Only time will tell.

However, it is hoped that now there will be plenty of research around the world at how to lower TMA in humans. 

0 comments:

Post a Comment